文献速递膀胱癌与上尿路尿路上皮癌

伴局灶高级别特征的Ta低级别膀胱尿路上皮癌预后更差吗?Roswell Park综合癌症中心的经验

Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience.
PubMed 文献 · Urology · 2024-06-22

该回顾性研究纳入2005至2023年接受经尿道膀胱肿瘤电切术的449例Ta期膀胱尿路上皮癌患者,分为低级别(48%)、局灶高级别特征(FHG,12%)和高级别(40%)三组。FHG组的高级别复发模式接近高级别组,但T分期进展和根治性膀胱切除术的比例更低。

要点

  • Ta期FHG组1、3、5年高级别无复发生存率分别为74%、53%、49%,介于低级别组与高级别组之间。
  • FHG组1、3、5年T分期无进展生存率分别为92%、82%、82%,高于高级别组。
  • FHG组1、3、5年免膀胱切除生存率分别为96%、94%、94%,接近低级别组。

核心结论

  • 作者认为,Ta期伴局灶高级别特征的患者在高级别复发方面似乎更接近Ta高级别病变,但发生T分期进展和转为根治性膀胱切除术的可能性更低。

研究设计与样本

  • 回顾性综述,纳入2005至2023年间接受经尿道膀胱肿瘤电切术的全部患者,共识别449例Ta期病变患者,分为低级别(48%)、局灶高级别特征(12%)和高级别(40%)三组,采用Kaplan-Meier法描绘高级别复发、T分期进展和免根治性膀胱切除生存。

主要发现

  • FHG组(32%)接受二次经尿道膀胱肿瘤电切术的比例高于低级别组(7%)和高级别组(29%)(P<.01)。
  • FHG组接受膀胱内治疗的比例高于低级别组(36% vs 20%),但低于高级别组(55%)(P<.01)。
  • FHG组接受根治性膀胱切除术的比例为7%,低于高级别组的20%和低级别组的11%(P=.01)。
  • 1、3、5年高级别无复发生存率:高级别组68%、52%、43%,FHG组74%、53%、49%,低级别组87%、79%、73%(log-rank P<.01)。
  • 1、3、5年T分期无进展生存率:高级别组84%、77%、70%,FHG组92%、82%、82%,低级别组94%、89%、85%(log-rank P=.02);1、3、5年免膀胱切除生存率:高级别组92%、84%、80%,FHG组96%、94%、94%,低级别组99%、95%、92%(log-rank P<.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the management and outcomes of patients with Ta predominantly low-grade urothelial carcinoma with focal high-grade features (FHG) (<5%), compared to those with Ta low grade (LG) and Ta high grade (HG). METHODS: Retrospective review of all patients who underwent transurethral resection of bladder tumor between 2005 and 2023. Patients with Ta disease were identified and categorized into LG, FHG, and HG. Kaplan Meier method was used to depict high-grade recurrence, T-stage progression, and radical cystectomy-free survival. RESULTS: Four hundred forty-nine patients with Ta disease were identified (LG 48%, FHG 12%, and HG 40%). Patients with FHG (32%) had a second-look transurethral resection of bladder tumor more frequently compared to LG (7%) and HG (29%) (P <.01). They received intravesical therapy more frequently compared to LG (36% vs 20%) but lower than HG (55%) (P <.01). They received radical cystectomy less frequently (7% compared to 20% for HG and 11% for LG, P = .01). HG recurrence-free survival at 1, 3, and 5years was HG (68%, 52%, and 43%), FHG (74%, 53%, and 49%), and LG (87%, 79%, and 73%) (log-rank P <.01). T progression-free survival at 1, 3, and 5years was HG (84%, 77%, and 70%), FHG (92%, 82%, and 82%), and LG (94%, 89%, and 85%) (log-rank P = .02). Cystectomy-free survival at 1, 3, and 5years was HG (92%, 84%, and 80%), FHG (96%, 94%, and 94%), and LG (99%, 95%, and 92%) (log-rank P <.01). CONCLUSION: Patients with Ta FHG seem to behave more like Ta HG disease in terms of high-grade recurrences, but they are less likely to experience T-stage progression and convert to cystectomy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Abou Heidar N, Mahmood AW, Khan M, et al. Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience. Urology. 2024. PMID: 38914229. doi:10.1016/j.urology.2024.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。